A RANDOMIZED DOUBLE-BLIND PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM- BASED THERAPY AS FIRST LINE TREATMENT OF STAGE III OR IV NON-MUCINOUS EPITHELIAL OVARIAN CANCER
Brief description of study
You are being asked to be in this research study because you have ovarian cancer. The current standard of care (SOC) for the treatment of ovarian cancer is paclitaxel and carboplatin, with or without bevacizumab. Your Study Doctor will determine if you should receive bevacizumab with paclitaxel and carboplatin. This study is being done to determine if adding the investigational drugs (TSR-042 - immunotherapy and niraparib - PARP inhibitor) to SOC delays or prevents ovarian cancer from coming back.
Clinical Study Identifier: s18-00572
ClinicalTrials.gov Identifier: NCT03602859
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
